[HTML][HTML] Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
Q He, J Liu, X Cai, M He, C Li, H Liang… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background Several randomized controlled trials have suggested that adjuvant epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
[PDF][PDF] Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
Q He, J Liu, X Cai, M He, C Li, H Liang, B Cheng, X Xia… - researchgate.net
Background: Several randomized controlled trials have suggested that adjuvant epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
[HTML][HTML] Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
Q He, J Liu, X Cai, M He, C Li, H Liang… - Translational Lung …, 2021 - tlcr.amegroups.org
Background: Several randomized controlled trials have suggested that adjuvant epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
Q He, J Liu, X Cai, M He, C Li… - Translational lung …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Several randomized controlled trials have suggested that adjuvant epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
[PDF][PDF] Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
Q He, J Liu, X Cai, M He, C Li, H Liang, B Cheng, X Xia… - cdn.amegroups.cn
Background: Several randomized controlled trials have suggested that adjuvant epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations.
Q He, J Liu, X Cai, M He, C Li, H Liang… - Translational Lung …, 2021 - europepmc.org
Background Several randomized controlled trials have suggested that adjuvant epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
[引用][C] Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
Q He, J Liu, X Cai, M He, C Li, H Liang… - Translational Lung …, 2021 - tlcr.amegroups.org
Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy
in resected NSCLC patients with sensitive EGFR mutations - He - Translational Lung Cancer …
in resected NSCLC patients with sensitive EGFR mutations - He - Translational Lung Cancer …